105 related articles for article (PubMed ID: 2325571)
41. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
[TBL] [Abstract][Full Text] [Related]
42. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide.
Miller PD; Bilezikian JP; Diaz-Curiel M; Chen P; Marin F; Krege JH; Wong M; Marcus R
J Clin Endocrinol Metab; 2007 Sep; 92(9):3535-41. PubMed ID: 17609307
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of calcitriol in treating glucocorticoidinduced osteoporosis in patients with nephrotic syndrome: an open-label, randomized controlled study.
Chen Y; Wan JX; Jiang DW; Fu BB; Cui J; Li GF; Chen CM
Clin Nephrol; 2015 Nov; 84(5):262-9. PubMed ID: 26396095
[TBL] [Abstract][Full Text] [Related]
44. Calcitriol and calcium carbonate therapy in early chronic renal failure.
Bianchi ML; Colantonio G; Campanini F; Rossi R; Valenti G; Ortolani S; Buccianti G
Nephrol Dial Transplant; 1994; 9(11):1595-9. PubMed ID: 7870349
[TBL] [Abstract][Full Text] [Related]
45. Vitamin D-mediated calcium absorption in patients with clinically stable Crohn's disease: a pilot study.
Kumari M; Khazai NB; Ziegler TR; Nanes MS; Abrams SA; Tangpricha V
Mol Nutr Food Res; 2010 Aug; 54(8):1085-91. PubMed ID: 20306476
[TBL] [Abstract][Full Text] [Related]
46. Effect of calcium supplementation on bone loss in postmenopausal women.
Reid IR; Ames RW; Evans MC; Gamble GD; Sharpe SJ
N Engl J Med; 1993 Feb; 328(7):460-4. PubMed ID: 8421475
[TBL] [Abstract][Full Text] [Related]
47. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.
Khan SA; Kanis JA; Vasikaran S; Kline WF; Matuszewski BK; McCloskey EV; Beneton MN; Gertz BJ; Sciberras DG; Holland SD; Orgee J; Coombes GM; Rogers SR; Porras AG
J Bone Miner Res; 1997 Oct; 12(10):1700-7. PubMed ID: 9333131
[TBL] [Abstract][Full Text] [Related]
48. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
Overgaard K; Hansen MA; Nielsen VA; Riis BJ; Christiansen C
Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
[TBL] [Abstract][Full Text] [Related]
49. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
Tolino A; Romano L; Ronsini S; Riccio S; Montemagno U
Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
[TBL] [Abstract][Full Text] [Related]
50. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women.
Christiansen C; Riis BJ
J Clin Endocrinol Metab; 1990 Oct; 71(4):836-41. PubMed ID: 2205624
[TBL] [Abstract][Full Text] [Related]
51. Dietary phylloquinone depletion and repletion in postmenopausal women: effects on bone and mineral metabolism.
Martini LA; Booth SL; Saltzman E; do Rosário Dias de Oliveira Latorre M; Wood RJ
Osteoporos Int; 2006; 17(6):929-35. PubMed ID: 16547688
[TBL] [Abstract][Full Text] [Related]
52. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
53. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
[TBL] [Abstract][Full Text] [Related]
54. Intestinal calcium absorption in men with spinal osteoporosis.
Need AG; Morris HA; Horowitz M; Scopacasa E; Nordin BE
Clin Endocrinol (Oxf); 1998 Feb; 48(2):163-8. PubMed ID: 9579227
[TBL] [Abstract][Full Text] [Related]
55. Relationships between intestinal calcium absorption, serum vitamin D metabolites and smoking in postmenopausal women.
Need AG; Kemp A; Giles N; Morris HA; Horowitz M; Nordin BE
Osteoporos Int; 2002 Jan; 13(1):83-8. PubMed ID: 11883410
[TBL] [Abstract][Full Text] [Related]
56. Long-term effect of calcium supplementation on bone loss in perimenopausal women.
Elders PJ; Lips P; Netelenbos JC; van Ginkel FC; Khoe E; van der Vijgh WJ; van der Stelt PF
J Bone Miner Res; 1994 Jul; 9(7):963-70. PubMed ID: 7942164
[TBL] [Abstract][Full Text] [Related]
57. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial.
Matsumoto T; Miki T; Hagino H; Sugimoto T; Okamoto S; Hirota T; Tanigawara Y; Hayashi Y; Fukunaga M; Shiraki M; Nakamura T
J Clin Endocrinol Metab; 2005 Sep; 90(9):5031-6. PubMed ID: 15972580
[TBL] [Abstract][Full Text] [Related]
58. 1,25-Dihydroxyvitamin D3 receptors in peripheral blood mononuclear cells from patients with postmenopausal osteoporosis.
Martínez J; Olmos JM; Amado JA; Riancho JA; Freijanes J; González-Macías J
Bone Miner; 1993 Dec; 23(3):207-12. PubMed ID: 8148665
[TBL] [Abstract][Full Text] [Related]
59. Is heritability a risk factor for postmenopausal osteoporosis?
Hansen MA; Hassager C; Jensen SB; Christiansen C
J Bone Miner Res; 1992 Sep; 7(9):1037-43. PubMed ID: 1414496
[TBL] [Abstract][Full Text] [Related]
60. Bone responsiveness to parathyroid hormone in normal and osteoporotic postmenopausal women.
Tsai KS; Ebeling PR; Riggs BL
J Clin Endocrinol Metab; 1989 Nov; 69(5):1024-7. PubMed ID: 2793989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
